Study of Trastuzumab Deruxtecan (T-DXd) vs Investigator's Choice Chemotherapy in HER2-low, Hormone Receptor Positive, Metastatic Breast Cancer
Clinical trial NCT04494425 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT04494425
- Sponsor
- AstraZeneca
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2020-07-24
- Primary completion
- 2024-03-18
- Enrollment
- 866
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.